Oxidative Medicine and Cellular Longevity · 2019 · 42 citations · 64 references
Life SciencesNeurobiologyNeuroscienceMolecular NeuroscienceNeuropharmacologySynaptic PlasticityAlzheimer DiseaseDementia TreatmentNeurodegeneration MechanismsNeurodegenerative DiseasesNeurodegenerative DisordersNeuroprotectionAlzheimer Disease NeuroprotectionAlzheimer's Disease ModelsChromatography-based MetabolomicsEnergy Metabolism RegulationMurine ModelsNeurodegenerative Disease MechanismsTraditional Chinese MedicineTraditional Herbal Medicine
Alzheimer’s disease (AD) is a common neurodegenerative disease, characterized by cognitive dysfunction; however, the therapeutic strategies are not fully understood. Huang-Lian-Jie-Du-Decoction (HLJDD) is a famous traditional Chinese herbal formula that has been widely used clinically to treat dementia. Recently, according to previous study and our clinical practice, we generate a new modification of HLJDD (named modified-HLJDD). In this study, we indicated that modified-HLJDD attenuated learning and memory deficiencies in A β 1-42 oligomer-induced AD model, and we confirmed the exact metabolites in modified-HLJDD solution, as compared with HLJDD by UHPLC-Q-TOF-MS. Using GC-Q-TOF/MS-based metabolomics, we identified adenosine as the potential significant metabolite, responsible for modified-HLJDD regulating energy metabolism and synaptic plasticity in AD model. We also revealed that the potential underlying mechanism of modified-HLJDD in AD model may involve NMDA receptor-mediated glutamatergic transmission and adenosine/ATPase/AMPK cascade. Moreover, we also indicated the differential gut microbiota which mainly involved Firmicutes , Bacteroidetes , Proteobacteria , and Actinobacteria at the phylum level upon modified-HLJDD treatment in AD model. Based on the correlation of metabolomic analysis with microbiome analysis, we clarified that Dorea is the most affected microbiota with adenosine upon modified-HLJDD treatment in AD model. Thus, our study suggests that modified-HLJDD may serve as a potential therapeutic drug in treating AD.
64
Gut microbiome alterations in Alzheimer’s disease
N. Vogt, Robert L. Kerby, Kimberly A. Dill‐McFarland et al. · Scientific Reports · 2017 · 2.1K citations · Full text
Trial of Solanezumab for Mild Dementia Due to Alzheimer’s Disease
Lawrence S. Honig, Bruno Vellas, Merçé Boada et al. · New England Journal of Medicine · 2018 · 1K citations · Full text
Medicine, Neurology, Pharmacology +17
Gut Microbiota is Altered in Patients with Alzheimer’s Disease
Zhen‐Qian Zhuang, Lin‐Lin Shen, Weiwei Li et al. · Journal of Alzheimer s Disease · 2018 · 870 citations
Structural basis for AMP binding to mammalian AMP-activated protein kinase
Bing Xiao, Richard Heath, Peter Saiu et al. · Nature · 2007 · 585 citations